Selective antagonist of α3β2 nAChR receptors
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | alpha-conotoxin PnIA;705300-84-1;A-CONOTOXIN PNIA;CHEMBL4443205;alpha-Conotoxin PnIA TFA;GTPL3982;BDBM50516319;AKOS024457442;DA-79161;Q27074398;S-705300-84-1; |
M.F/Formula | C65H95N19O22S4 |
M.W/Mr. | 1622.8 |
Sequence | One Letter Code:GCCSLPPCAANNPDYC Three Letter Code:H-Gly-Cys(1)-Cys(2)-Ser-Leu-Pro-Pro-Cys(1)-Ala-Ala-Asn-Asn-Pro-Asp-Tyr-Cys(2)-NH2 |
Labeling Target | α3β2 nAChR receptors |
Appearance | White lyophilised solid |
Purity | >97% |
Activity | Antagonist |
InChI | InChI=1S/C65H95N19O22S4/c1-29(2)18-37-63(104)84-17-7-10-46(84)65(106)83-16-6-9-45(83)62(103)81-42-27-110-108-26-41(72-49(89)23-66)59(100)80-43(60(101)78-39(24-85)57(98)76-37)28-109-107-25-40(51(69)92)79-54(95)34(19-32-11-13-33(86)14-12-32)74-56(97)36(22-50(90)91)75-61(102)44-8-5-15-82(44)64(105)38(21-48(68)88)77-55(96)35(20-47(67)87)73-53(94)31(4)70-52(93)30(3)71-58(42)99/h11-14,29-31,34-46,85-86H,5-10,15-28,66H2,1-4H3,(H2,67,87)(H2,68,88)(H2,69,92)(H,70,93)(H,71,99)(H,72,89)(H,73,94)(H,74,97)(H,75,102)(H,76,98)(H,77,96)(H,78,101)(H,79,95)(H,80,100)(H,81,103)(H,90,91)/t30-,31-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1 |
InChI Key | VUVGEYBNLLGGBG-MVPSLEAZSA-N |
Isomeric SMILES | C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)NC(=O)CN)C(=O)N[C@H](C(=O)N1)C)CC(C)C)CO)C(=O)N)CC6=CC=C(C=C6)O)CC(=O)O)CC(=O)N)CC(=O)N |
BoilingPoint | N/A |
Melting Point | N/A |
2. Implications of ligand-receptor binding kinetics on GLP-1R signalling
4. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.